Volume : 08, Issue : 06, June – 2021

Title:

28.ADVANCES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE MANAGEMENT AND ROLE OF OXYGEN THERAPY

Authors :

Mohammed Saeed Alghamdi, Osama Abduallah Alzahrani, Mohammed Ayed Ali Hassosah, Abdulsalam Rashed alshehri

Abstract :

Introduction: Chronic obstructive pulmonary disease (COPD) is a global health problem and is anticipated to be the third leading cause of mortality worldwide by 2020. It is characterized by persistent airflow limitation and acute episodes of symptom worsening, or exacerbations, that are beyond normal daily variation and that lead to a change in treatment.
Aim of work: This review aims at discussing the various therapies and new management strategies developed for chronic obstructive pulmonary disease and the role of oxygen therapy.
Methodology: The review is a comprehensive research of PUBMED, Google Scholar, and WHO official page from the year 1992 to 2019.
Conclusion: Recent studies have shown that withdrawal of inhaled corticosteroids (ICS) is safe in some patients, making the combination of LAMA/LABA pharmacotherapy a judicious option for many patients, particularly those who are on a single long-acting bronchodilator. The growth of new dual-agent long-acting bronchodilator inhalers may decrease the excessive over-prescription of combination ICS/LABAs. However, additional investigations are needed to establish whether bronchoscopic lung volume reduction can be a potential approved therapy in patients with severe COPD.

Cite This Article:

Please cite this article in press Osama Abduallah Alzahrani et al., Advances In Chronic Obstructive Pulmonary Disease Management And Role Of Oxygen Therapy.., Indo Am. J. P. Sci, 2021; 08(06).

Number of Downloads : 10

References:

1. Raherison C, & Girodet P O (2009) Epidemiology of COPD. Eur Respir Rev; 18: 213–21.
2. Riley C M, & Sciurba F C (2019). Diagnosis and outpatient management of chronic obstructive pulmonary disease: a review. Jama, 321(8), 786-797.
3. American Thoracic Society. Standards for Diagnosis and Care of Patients with COPD. American Journal of Respiratory Care Medicine. (1995) ; 152: S77-S120.
4. Calverley P M, Anderson J A, Celli B, Ferguson G T, Jenkins C, Jones P W, & Vestbo J (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine, 356(8), 775-789.
5. Cazzola M, Page C P, Calzetta L, & Matera M G (2012). Pharmacology and therapeutics of bronchodilators. Pharmacological Reviews, 64(3), 450-504.
6. Cazzola M, & Matera M G (2014). Bronchodilators: current and future. Clinics in chest medicine, 35(1), 191-201.
7. Ferguson G T, Feldman G J, Hofbauer P, Hamilton A, Allen L, Korducki L, & Sachs P (2014). Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. International journal of chronic obstructive pulmonary disease, 9, 629.
8. Jones P W, Rennard S I, Agusti A, Chanez P, Magnussen H, Fabbri L, & Gil E G (2011). Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respiratory research, 12(1), 1-10.
9. Jones P W, Singh D, Bateman E D, Agusti A, Lamarca R, de Miquel G, & Gil E G (2012). Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal, 40(4), 830-836.
10. Van Noord J A, Aumann J L, Janssens E, Smeets J J, Zaagsma J, Mueller A, & Cornelissen P J G (2010). Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respiratory medicine, 104(7), 995-1004.
11. Donohue J F, Maleki-Yazdi M R, Kilbride S, Mehta R, Kalberg C, & Church A (2013). Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respiratory medicine, 107(10), 1538-1546.
12. National Emphysema Treatment Trial Research Group. (2003). A randomized trial comparing lung-volume–reduction surgery with medical therapy for severe emphysema. New England Journal of Medicine, 348(21), 2059-2073.
13. Davey C, Zoumot Z, Jordan S, McNulty W H, Carr D H, Hind M D,& Hopkinson N S (2015). Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. The Lancet, 386(9998), 1066-1073.
14. Morrison D A, & Stovall J R (1992). Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. Chest, 102(2), 542-550.